There are more than 30 types of muscular dystrophy and over 7,000 known mutations in the Duchenne gene alone, which has ...

SK pharmteco today announced details of its ongoing strategic manufacturing partnership with Genethon, a France-based pioneering nonprofit research and development organization dedicated to gene ...

Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.

Duchenne muscular dystrophy (DMD) is a genetic disease in which muscle cells fail to produce a protein called dystrophin. Unlike some other forms of muscular dystrophy, in Duchenne there is a complete ...

Sonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Today, the world stands at a crossroads in genetic medicine ...

Researchers at the USF Health Morsani College of Medicine have identified a potential pathway that could protect cardiac ...

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) ...

Add Yahoo as a preferred source to see more of our stories on Google. When Conner Curran was first diagnosed with Duchenne muscular dystrophy at age 4, his parents were told there was nothing they ...

The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...

US biotech Dyne Therapeutics has moved closer to a possible first approval after the US Food and Drug Administration accepted ...

A Northwestern Medicine study has uncovered how chronic defects in muscle membrane repair can fuel harmful inflammation. The ...